

Special Issue

Clinical Trials for Thoracic Cancers

Message from the Guest Editor

Thoracic cancers, including lung, thymic, and pleural malignancies, remain among the most lethal oncologic entities worldwide. In recent years, clinical research has witnessed a paradigm shift from traditional cytotoxic therapies to biomarker-driven treatments, immunoncology, and multimodal strategies. Innovations in trial design have accelerated the dynamic evolution of clinical trials, the increasing integration of artificial intelligence, and the growing emphasis on real-world evidence to complement randomized controlled trials.

This Special Issue aims to capture the breadth of ongoing progress in thoracic oncology clinical trials, focusing on innovative methodologies, translational applications, and patient-centered outcomes. We welcome original research, systematic reviews, and perspectives that address key topics such as precision medicine, novel endpoints, adaptive trial models, and the implementation of multidisciplinary treatment pathways. Contributions are especially encouraged in exploring neoadjuvant and adjuvant settings, minimally invasive interventions, and longitudinal analyses of patient-reported outcomes.

Guest Editor

Dr. Monica Casiraghi

1. Department of Thoracic Surgery, European Institute of Oncology–IEO, Milan, Italy
2. Department of Oncology and Hemato-Oncology, University of Milan, 20141 Milan, Italy

Deadline for manuscript submissions

5 July 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/237630

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)